Programming Human Dendritic Cells with mRNA

  • Jaewoo Lee
  • David Boczkowski
  • Smita Nair
Part of the Methods in Molecular Biology book series (MIMB, volume 969)


Transfecting with in vitro transcribed, protein-encoding mRNA is a simple yet effective method to express high levels of the desired RNA-encoded proteins in primary cells. Cells can be transfected with antigen-encoding mRNA, which is translated into protein and is processed by the cellular antigen-processing pathway to generate antigen-presenting cells. Another elegant and increasingly popular application is to transfect cells with mRNA that encodes immune modulating molecules (cytokines, chemokines, toll-like receptors (TLRs), immune receptor ligands, immune receptor targeting antibodies) which, when translated into protein, can program cell behavior and/or function. In this chapter we describe an efficient method to deliver mRNA into human dendritic cells (DCs) by electroporation. This is currently the method of choice to deliver mRNA into antigen-presenting cells for generating vaccines for cancer immunotherapy.

Key words

Dendritic cells Electroporation RNA-based programming RNA transfection 


  1. 1.
    Zhou LJ, Tedder TF (1996) CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588–2592PubMedCrossRefGoogle Scholar
  2. 2.
    Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296PubMedCrossRefGoogle Scholar
  3. 3.
    Nair S, Boczkowski D, Pruitt S, Urban J (2011) RNA in cancer vaccine therapy. In: Bot A, Obrocea M, Marincola F (eds) Cancer vaccines: from research to clinical practice pp 217–231Google Scholar
  4. 4.
    Bringmann A, Held SA, Heine A, Brossart P (2010) RNA vaccines in cancer treatment. J Biomed Biotechnol 2010(623687):1–12CrossRefGoogle Scholar
  5. 5.
    Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263PubMedCrossRefGoogle Scholar
  6. 6.
    Boczkowski D, Lee J, Pruitt S, Nair S (2009) Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther 16(12):900–911PubMedCrossRefGoogle Scholar
  7. 7.
    Boczkowski D, Nair S (2010) RNA as performance-enhancers for dendritic cells. Expert Opin Biol Ther 10:563–574PubMedCrossRefGoogle Scholar
  8. 8.
    Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, Francois V, Colau D, van der Bruggen P, Neyns B, Thielemans K (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15:3366–3375PubMedCrossRefGoogle Scholar
  9. 9.
    Bontkes HJ, Kramer D, Ruizendaal JJ, Meijer CJ, Hooijberg E (2008) Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol 127:375–384PubMedCrossRefGoogle Scholar
  10. 10.
    Cisco RM, Abdel-Wahab Z, Dannull J, Nair S, Tyler DS, Gilboa E, Vieweg J, Daaka Y, Pruitt SK (2004) Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol 172:7162–7168PubMedGoogle Scholar
  11. 11.
    Dannull J, Lesher DT, Holzknecht R, Qi W, Hanna G, Seigler H, Tyler DS, Pruitt SK (2007) Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood 110:4341–4350PubMedCrossRefGoogle Scholar
  12. 12.
    Dannull J, Nair S, Su Z, Boczkowski D, DeBeck C, Yang B, Gilboa E, Vieweg J (2005) Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105:3206–3213PubMedCrossRefGoogle Scholar
  13. 13.
    Lee J, Dollins CM, Boczkowski D, Sullenger BA, Nair S (2008) Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology 125:229–240PubMedCrossRefGoogle Scholar
  14. 14.
    Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S (2011) Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 41(12):3553–3563PubMedCrossRefGoogle Scholar
  15. 15.
    Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatinovich J, Calderhead D, Healey D, Nicolette CA (2008) Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol 9:90PubMedCrossRefGoogle Scholar
  16. 16.
    Zhao Y, Boczkowski D, Nair SK, Gilboa E (2003) Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood 102:4137–4142PubMedCrossRefGoogle Scholar
  17. 17.
    Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49–56PubMedCrossRefGoogle Scholar
  18. 18.
    Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E (2000) Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60:1028–1034PubMedGoogle Scholar
  19. 19.
    Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472PubMedCrossRefGoogle Scholar
  20. 20.
    Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964–971PubMedCrossRefGoogle Scholar
  21. 21.
    Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16:364–369PubMedCrossRefGoogle Scholar
  22. 22.
    Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011–1017PubMedCrossRefGoogle Scholar
  23. 23.
    Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE (2001) Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG. RNA 7:1486–1495PubMedGoogle Scholar
  24. 24.
    Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, vol 1–3, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 7.43–7.45Google Scholar
  25. 25.
    Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A (2000) Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 7:2028–2035PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of SurgeryDuke University Medical CenterDurhamUSA

Personalised recommendations